🇺🇸 FDA
Patent

US 8609706

Compounds and methods for inhibiting the interaction of BCL proteins with binding partners

granted A61KA61K31/42A61K31/422

Quick answer

US patent 8609706 (Compounds and methods for inhibiting the interaction of BCL proteins with binding partners) held by Infinity Discovery, Inc. expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Infinity Discovery, Inc.
Grant date
Tue Dec 17 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/42, A61K31/422, A61K31/427, A61K31/4439